-
Dr. Sujun Zheng: From Hepatitis to Liver Cancer – Exploring Comprehensive Management of Liver Diseases
HBV infection is a major cause of chronic hepatitis B (CHB), cirrhosis, liver failure, and hepatocellular carcinoma. Despite the development of new drugs and advancements in antiviral therapy, a complete cure for CHB remains a clinical challenge. The burden of liver disease in China is still heavy, and the implementation of high-quality liver disease management…
-
Showcasing Chinese Wisdom on the International Stage: The 25th International AIDS Conference, China Special Session
From July 22-26, 2024, the 25th International AIDS Conference (AIDS 2024) was held in Munich, Germany. As a key player in the global fight against AIDS, China has consistently made significant contributions. At this conference, the China Special Session, titled “Ending AIDS in China: Challenges and Strategies,” was jointly organized by the Chinese Association of…
-
Voice of China in AIDS Research丨Dr. Fujie Zhang’s Team: Efficacy of Long-term Antiretroviral Therapy in Chinese Children and Adolescents with HIV
From July 22-26, 2024, the 25th International AIDS Conference took place in Munich, Germany, gathering 15,000 professionals and advocates from around the world to discuss the latest advancements and future challenges in AIDS prevention and treatment. At the conference, Dr. Hanxi Zhang from Dr. Fujie Zhang’s team at Beijing Ditan Hospital presented a multicenter, prospective,…
-
2024 CUDA丨Dr. Xiongjun Ye: Mastering the Characteristics and Approaches of Robot-Assisted Partial Nephrectomy, Clarifying the Path to Optimization
From August 8th to 11th, 2024, the Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association (CUDA) was held in Xi’an. Organized by the Chinese Medical Doctor Association and the Urology Physicians Branch, and hosted by Xijing Hospital of the Air Force Medical University, with support from the Urology Physicians Branch…
-
JAMA Oncol | Tumor Mutational Burden and Its Response to Immune Checkpoint Inhibitors in Metastatic Castration-Resistant Prostate Cancer
This study explored the relationship between tumor mutational burden (TMB) status and the efficacy and prognosis of mCRPC patients treated with the immune checkpoint inhibitor pembrolizumab. The study retrospectively analyzed…
-
2024 COMB丨Dr. Songqing Ye: Exploring the Development of CDK4/6 Inhibitors, ADCs, and Immunotherapy in Early-Stage Breast Cancer
From August 2-4, 2024, the 7th Oncology Precision Diagnosis and Treatment Conference and the 10th Breast Cancer Individualized Treatment Conference (COMB), organized by the China Cancer Foundation and Beijing Breast Disease Prevention Society, was grandly held in Beijing. The conference brought together the latest advances in individualized precision treatment for breast cancer in China, providing…
-
2024 ESMO BC | Exploratory Analysis of the SERENA-2 Study Suggests Early Changes in ctDNA Predict Better Response to Camizestrant Treatment
The SERENA-2 study evaluated the efficacy and safety of different doses of Camizestrant (75 mg, 150 mg) compared to fulvestrant in patients with advanced ER+/HER2- breast cancer. The results showed that the median PFS in the Camizestrant groups was similar regardless of ESR1m status or dosage. Researchers further conducted an exploratory analysis of the SERENA-2…
-
JCO | Is It Too Early to Use Radiographic Progression-Free Survival as a Surrogate Endpoint in Metastatic Hormone-Sensitive Prostate Cancer?
Metastatic hormone-sensitive prostate cancer (mHSPC) is a heterogeneous disease state and represents a critical time window for improving survival in advanced prostate cancer, requiring comprehensive and personalized treatment. As diagnostic and therapeutic strategies continue to advance, the management and assessment of mHSPC have become increasingly complex. Several studies have already evaluated the efficacy of new…
Connecting Medical Expertise through Media